Sundar S, Pandey K, Mondal D, Madhukar M, Kamal Topno R, et al.
2024-06-20 • PLOS Neglected Tropical Diseases
2024-06-20 • PLOS Neglected Tropical Diseases
BACKGROUND In Southeast Asia, treatment is recommended for all patients with post-kala-azar dermal leishmaniasis (PKDL). Adherence to the first-line regimen, twelve weeks of miltefos...
Mahajan R, Das P, Isaakidis P, Sunyoto T, Sagili KD, et al.
2015-06-30 • Clinical Infectious Diseases
2015-06-30 • Clinical Infectious Diseases
There are considerable numbers of patients co-infected with Human Immunodeficiency Virus (HIV) and Visceral Leishmaniasis (VL) in the VL-endemic areas of Bihar, India. These patients are...
Burza S, Mahajan R, Singh A, van Griensven J, Pandey K, et al.
2014-08-07 • PLOS Neglected Tropical Diseases
2014-08-07 • PLOS Neglected Tropical Diseases
Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease endemic in the Indian state of Bihar, while HIV/AIDS is an emerging disease in this region. A 2011 obs...
Mahajan R, Owen SI, Kazmi S, Das P, Pandey K, et al.
2021-05-19 • MSF Scientific Days International 2021: Research
2021-05-19 • MSF Scientific Days International 2021: Research
INTRODUCTION People co-infected with visceral leishmaniasis and HIV (VL-HIV) typically present with advanced HIV disease and in poor clinical condition. The reasons for this are comp...
Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G, et al.
2014-01-02 • PLOS Neglected Tropical Diseases
2014-01-02 • PLOS Neglected Tropical Diseases
Visceral Leishmaniasis (VL; also known as Kala-azar) is an ultimately fatal disease endemic in Bihar. A 2007 observational cohort study in Bihar of 251 patients with VL treated with 20 m...
BACKGROUND In 2010, WHO recommended the use of new short-course treatment regimens in kala-azar elimination efforts for the Indian subcontinent. Although phase 3 studies have shown e...
Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G, et al.
2014-01-02 • PLOS Neglected Tropical Diseases
2014-01-02 • PLOS Neglected Tropical Diseases
A proportion of all immunocompetent patients treated for visceral leishmaniasis (VL) are known to relapse; however, the risk factors for relapse are not well understood. With the support...
Burza S, Mahajan R, Kazmi S, Alexander N, Kumar D, et al.
2022-10-15 • Clinical Infectious Diseases
2022-10-15 • Clinical Infectious Diseases
BACKGROUND Visceral leishmaniasis (VL) in patients living with Human-Immunodeficiency-Virus (HIV) present an increasingly important patient cohort in areas where both infections are ...
BACKGROUND:
An earlier open label, prospective, non-randomized, non-comparative, multi-centric study conducted within public health facilities in Bihar, India (CTRI/2012/08/002891) ...
Owen SI, Burza S, Verma N, Mahajan R, Harshana A, et al.
2021-04-30 • BMJ Open
2021-04-30 • BMJ Open
INTRODUCTION HIV coinfection presents a challenge for diagnosis of visceral leishmaniasis (VL). Invasive splenic or bone marrow aspiration with microscopic visualisation of Leishmani...
Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N, et al.
2011-10-01 • Clinical Infectious Diseases
2011-10-01 • Clinical Infectious Diseases
Reports on treatment outcomes of visceral leishmaniasis (VL)-human immunodeficiency virus (HIV) coinfection in India are lacking. To our knowledge, none have studied the efficacy of lipo...
Burza S, Sinha PK, Mahajan R, Gonzalez Sanz M, Lima MA, et al.
2014-01-02 • PLOS Neglected Tropical Diseases
2014-01-02 • PLOS Neglected Tropical Diseases
The skin disorder Post Kala-Azar Dermal Leishmaniasis (PKDL) occurs in up to 10% of patients treated for visceral leishmaniasis (VL) in India. The pathogenesis of PKDL is not yet fully u...
